AbbVie MAVYRET — Net revenues increased by 3.8% to $324.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.3%, from $291.00M to $324.00M. Over 4 years (FY 2021 to FY 2025), MAVYRET — Net revenues shows a downward trend with a -6.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase suggests sustained market share or successful patient access strategies, while a decrease indicates potential market saturation, generic competition, or a shift in the standard of care.
This metric represents the total net sales generated from the specific pharmaceutical product line used for the treatmen...
Comparable to specific therapeutic product revenue lines reported by other large-cap pharmaceutical companies, often evaluated against the backdrop of patent cliffs and competitive entry.
abbv_segment_mavyret_net_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $442.00M | $426.00M | $427.00M | $380.00M | $398.00M | $383.00M | $380.00M | $364.00M | $387.00M | $370.00M | $309.00M | $349.00M | $369.00M | $302.00M | $291.00M | $306.00M | $375.00M | $312.00M | $324.00M |
| QoQ Change | — | -3.6% | +0.2% | -11.0% | +4.7% | -3.8% | -0.8% | -4.2% | +6.3% | -4.4% | -16.5% | +12.9% | +5.7% | -18.2% | -3.6% | +5.2% | +22.5% | -16.8% | +3.8% |
| YoY Change | — | — | — | — | -10.0% | -10.1% | -11.0% | -4.2% | -2.8% | -3.4% | -18.7% | -4.1% | -4.7% | -18.4% | -5.8% | -12.3% | +1.6% | +3.3% | +11.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.